Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin vs Standard Therapy in S. aureus Bacteremia
NCT02208063Phase 3Terminated
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Apr 2018
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of telavancin in Staphylococcus aureus bacteremia (SAB), infective endocarditis (IE), sponsored by Cumberland Pharmaceuticals. Started Dec 2014; status: terminated.
02
Drugs
telavancin
03
Conditions
Staphylococcus aureus bacteremia (SAB)infective endocarditis (IE)
Beyond the preview
Go deeper on NCT02208063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208063.